KR102179848B1 - 종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용 - Google Patents

종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용 Download PDF

Info

Publication number
KR102179848B1
KR102179848B1 KR1020157000987A KR20157000987A KR102179848B1 KR 102179848 B1 KR102179848 B1 KR 102179848B1 KR 1020157000987 A KR1020157000987 A KR 1020157000987A KR 20157000987 A KR20157000987 A KR 20157000987A KR 102179848 B1 KR102179848 B1 KR 102179848B1
Authority
KR
South Korea
Prior art keywords
cells
tumor
stained
stained cells
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157000987A
Other languages
English (en)
Korean (ko)
Other versions
KR20150023760A (ko
Inventor
제롬 걀롱
프랑크 빠제스
베른하르트 믈레닉
Original Assignee
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
위니베르시떼 파리 데카르트
아시스땅스 퍼블리끄-오삐또 드 빠리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 위니베르시떼 파리 데카르트, 아시스땅스 퍼블리끄-오삐또 드 빠리 filed Critical 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Publication of KR20150023760A publication Critical patent/KR20150023760A/ko
Application granted granted Critical
Publication of KR102179848B1 publication Critical patent/KR102179848B1/ko
Assigned to 유니베르시떼 파리 시테 reassignment 유니베르시떼 파리 시테 권리지분의 전부이전등록 Assignors: 위니베르시떼 파리 데카르트
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G01N33/574—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020157000987A 2012-06-14 2013-06-14 종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용 Active KR102179848B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2012001446 2012-06-14
WOPCT/IB2012/001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (2)

Publication Number Publication Date
KR20150023760A KR20150023760A (ko) 2015-03-05
KR102179848B1 true KR102179848B1 (ko) 2020-11-17

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000987A Active KR102179848B1 (ko) 2012-06-14 2013-06-14 종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용

Country Status (13)

Country Link
US (1) US10317408B2 (https=)
EP (1) EP2861986B1 (https=)
JP (1) JP6449765B2 (https=)
KR (1) KR102179848B1 (https=)
CN (1) CN104541167B (https=)
AU (1) AU2013276470B2 (https=)
BR (1) BR112014031143B8 (https=)
CA (1) CA2873278C (https=)
DE (1) DE13731071T1 (https=)
ES (1) ES2902879T3 (https=)
IL (1) IL235738B (https=)
SG (1) SG11201408107RA (https=)
WO (1) WO2013186374A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ， インク． ＣＤ３、ＣＤ８、ＣＤ２０及びＦｏｘＰ３の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
EP3195191B1 (en) * 2014-09-03 2020-10-21 Ventana Medical Systems, Inc. Systems and methods for calculating immune scores
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
US10705088B2 (en) * 2015-10-23 2020-07-07 Novartis Ag Method of scoring a sample comprising tumor tissue
US20190309369A1 (en) * 2016-05-09 2019-10-10 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods for classifying patients with a solid cancer
EP3459046B1 (en) * 2016-05-18 2021-06-16 F. Hoffmann-La Roche AG Tumor proximity measure
US12158399B2 (en) * 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
US11048911B2 (en) * 2016-10-27 2021-06-29 Koninklijke Philips N.V. Apparatus for determining cellular composition information in one or more tissue samples
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
EP3921648A1 (en) * 2019-02-05 2021-12-15 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
CA3151629A1 (en) 2019-11-07 2021-05-14 Laura E. BENJAMIN Classification of tumor microenvironments
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
JP7741831B2 (ja) * 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
WO2023018085A1 (ko) * 2021-08-10 2023-02-16 주식회사 루닛 병리 슬라이드 이미지와 관련된 정보를 출력하는 방법 및 장치
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515148A (ja) * 2005-10-19 2009-04-09 アンセルム （アンスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 患者の癌の進行およびその転帰の生体外予後診断方法、および該方法を実施するための手段
JP2012503180A (ja) 2008-09-16 2012-02-02 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236268A1 (en) * 1995-11-30 1997-06-05 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
AU2006333078B2 (en) * 2005-12-19 2012-03-01 Ventana Medical Systems, Inc. Automated lean methods in anatomical pathology
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515148A (ja) * 2005-10-19 2009-04-09 アンセルム （アンスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 患者の癌の進行およびその転帰の生体外予後診断方法、および該方法を実施するための手段
JP2012503180A (ja) 2008-09-16 2012-02-02 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Niels Halama et al., 'The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic', OncoImmunology, 2012, Vol. 1, pp 62-66. 1부.*

Also Published As

Publication number Publication date
CN104541167A (zh) 2015-04-22
BR112014031143A2 (pt) 2017-08-08
IL235738A0 (en) 2015-01-29
BR112014031143B1 (pt) 2022-03-03
IL235738B (en) 2019-02-28
EP2861986B1 (en) 2021-11-10
ES2902879T3 (es) 2022-03-30
WO2013186374A1 (en) 2013-12-19
JP2015525349A (ja) 2015-09-03
DE13731071T1 (de) 2016-08-18
CN104541167B (zh) 2018-05-01
AU2013276470A1 (en) 2014-11-27
JP6449765B2 (ja) 2019-01-09
KR20150023760A (ko) 2015-03-05
US10317408B2 (en) 2019-06-11
SG11201408107RA (en) 2015-01-29
AU2013276470B2 (en) 2018-06-07
BR112014031143B8 (pt) 2022-11-22
US20150153349A1 (en) 2015-06-04
CA2873278C (en) 2021-10-26
CA2873278A1 (en) 2013-12-19
EP2861986A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
KR102179848B1 (ko) 종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용
DK2939026T3 (en) IMAGE ANALYSIS FOR BREAST CANCER PROGRESS
Fox et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
US20110111435A1 (en) Detecting Cell Surface Markers
EP3117259B1 (en) Assessment of staining quality
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
JP2019534451A (ja) １つ又は複数の組織サンプルにおける細胞組成情報を決定する装置
KR20150023808A (ko) 조직 절편 내 단일 세포에서의 마커 정량
WO2017171720A1 (en) Digital image analysis of inflammatory cells and mediators of inflammation
Laokulrath et al. Invasive breast cancer reporting guidelines: ICCR, CAP, RCPath, RCPA datasets and future directions
Jagomast et al. Comparison of manual and automated digital image analysis systems for quantification of cellular protein expression
Jiang et al. Comparative study of different software in Ki67 assessment of breast cancer
CN115602313A (zh) 用于疾病疗效与生存预后预测的生物标志物及其用途
CN121100370A (zh) 信号聚集体定量的基准真值
Hasan Evaluation of cell line-derived xenografted tumors as controls for immunohistochemical testing for estrogen receptors and progesterone receptors
Pinder et al. HER2 testing in the UK: further update to

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000